Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Castle Biosciences Inc

NASDAQ: CSTL · Industrial Applications and Services · 14 alerts · CIK 1447362

Share price
$32.75Close, Nov 16
Market cap
$1.01B
Shares outstanding
30.82MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Castle Biosciences Inc filings on SEC EDGAR ↗

4:12 PM ET 10-Q
Financial Results ▶ Call

Castle Biosciences Q3 2026 Results: Net Loss of $4.1M, Loss Widens

Castle Biosciences reported net revenues of $102.9 million for the third quarter of 2026, up from $83.0 million in 2025. Despite the revenue growth, the company realized a net loss of $4.1 million for the quarter, primarily driven by increased operating expenses in selling, general, and administrative functions.

Key figure
Net loss $4.1M
4:11 PM ET 8-K
Financial Results

Castle Biosciences Financial Results

Castle Biosciences reported Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, driven by strong volume growth in its TissueCypher test. The company raised its full-year 2026 revenue guidance to a range of $385-395 million and reported a net loss of $4.1 million for the quarter.

Term
Q3 2026

“Our team delivered another strong quarter, reflecting consistent execution across our portfolio. TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”

Derek Maetzold, president and chief executive officer of Castle Biosciences

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.